Hypercalcemia appeared in a patient with glucagonoma treated with octreotide acetate long-acting release.
- Author:
Min RUI
1
,
2
;
Li LI
;
Mao JIANG-FENG
;
Gu FENG
;
Zhu HUI-JUAN
;
Li WEN-HUI
;
Li YU-XIU
Author Information
1. Department of Endocrinology, Key Laboratory of Endocrinology of the Ministry of Health, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences &
2. Peking Union Medical College, Beijing 100730, China.
- Publication Type:Case Reports
- MeSH:
Antineoplastic Agents, Hormonal;
adverse effects;
Female;
Glucagonoma;
drug therapy;
Humans;
Hypercalcemia;
chemically induced;
Middle Aged;
Octreotide;
adverse effects;
Pancreatic Neoplasms;
drug therapy
- From:
Chinese Medical Sciences Journal
2012;27(3):182-184
- CountryChina
- Language:English
-
Abstract:
PABCREATIC neuroendocrine tumours are uncommon neoplasms of the pancreas. They may cause a clinical syndrome due to hormone overproduction. Glucagonoma is a rare kind of pancreatic tumors. Here we report a case of glucagonoma. Hypercalcemia occurred when the patient underwent octreotide acetate long-acting release.
